AVEO Pharmaceuticals, Inc.

NasdaqCM:AVEO Rapport sur les actions

Capitalisation boursière : US$521.4m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

AVEO Pharmaceuticals Gestion

Gestion contrôle des critères 3/4

Informations clés

Michael Bailey

Directeur général

US$2.9m

Rémunération totale

Pourcentage du salaire du PDG20.04%
Durée du mandat du directeur général8yrs
Propriété du PDG1.0%
Durée moyenne d'occupation des postes de direction2.7yrs
Durée moyenne du mandat des membres du conseil d'administration8yrs

Mises à jour récentes de la gestion

Recent updates

Seeking Alpha • Oct 18

AVEO Oncology shares jumped on acqusition by LG Chem for $15.00 per share in cash

LG Chem (OTCPK:LGCLF) will acquire AVEO for $15.00 per share in an all-cash transaction with an implied equity value of $566M on a fully diluted basis. AVEO shares jumped 38% premarket in response to the news as the transaction price represents a 43% premium to closing share price on October 17, 2022, as well as a 71% premium to its 30 trading day volume-weighted average price. Upon completion of the transaction, AVEO will operate as the U.S. commercial foundation for LG Chem Life Sciences’ oncology segment and will immediately establish LG Chem’s commercial presence in oncology through AVEO’s lead product, FOTIVDA (tivozanib), which received FDA approval in March 2021 for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. The transaction is expected to close in early 2023. LG Chem expects to finance the transaction with existing and available cash resources. AVEO expects to report Q3 results on Monday, November 7, 2022 but will not conduct an earnings conference call or provide financial guidance.
Article d’analyse • Oct 04

Here's Why AVEO Pharmaceuticals (NASDAQ:AVEO) Can Manage Its Debt Despite Losing Money

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
Seeking Alpha • Aug 15

A Current Assessment On AVEO Pharmaceuticals

Today, we put small oncology name AVEO Pharmaceuticals in the spotlight for the first time in three and a half years. The company is seeing good sales growth from its franchise drug that was approved in 2021 and is marching toward profitability as a company. An investment analysis follows in the paragraphs below. The income tax created more criminals than any other single act of government." - Barry Goldwater The last time I wrote about AVEO Pharmaceuticals, Inc. (AVEO) was after it was "sideswiped" by an FDA decision in early 2019. That article counseled patience, which was good advice in hindsight as the company eventually cleared that FDA hurdle. FOTIVDA, also known as Tivozanib, finally was approved approximately a year and a half ago for treating relapsed or refractory advanced renal cell carcinoma (R/R RCC) in a third-line setting. Company Website FOTIVDA is an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor. The drug should deliver just north of $100 million in sales this fiscal year. Therefore, it seems a good time to peak back in on this small but fast-growing oncology concern. An analysis follows below. Seeking Alpha Company Overview: AVEO Pharmaceuticals is located in Boston. The company is focused on developing and commercializing medicines for oncology. The stock currently trades at around eight bucks a share and sports an approximate market capitalization of $275 million. The company is currently enrolling patients in a Phase 3 'TiNivo-2' clinical trial evaluating tivozanib in combination with Bristol-Myers Squibb's (BMY) antibody nivolumab or OPDIVO. The study is targeting PD-1 and results will be compared to tivozanib monotherapy in patients with R/R RCC who have progressed following prior immune checkpoint inhibitor therapy. If the data is favorable, this could result in FDA approval of tivozanib in combination with OPDIVO in R/R RCC and expand the market opportunity for FOTIVDA into the larger second-line R/R RCC setting. The company is also developing Ficlatuzumab. This is a potent hepatocyte growth factor ((HGF)) immunoglobulin G1 (IgG1) inhibitory antibody that binds to the HGF ligand with high affinity and specificity. AVEO Pharmaceuticals has conducted a Phase 2 trial of ficlatuzumab as a single agent or in combination with cetuximab (ERBITUX®) in patients who relapsed or were refractory to prior immunotherapy, chemotherapy, and cetuximab (pan-refractory) with metastatic head and neck squamous cell carcinoma or HNSCC. The company has stated it expects to make a go/no-go decision on the initiation of a pivotal Phase 3 study of ficlatuzumab in HPV negative HNSCC following feedback from the FDA. The compound does have Fast Track designation for this indication, and management continues to seek a strategic partner to fund development expenses. Company Website The rest of AVEO's pipeline consists of earlier staged compounds and not germane to this analysis. First Quarter Results: On August 4th, the company posted second quarter numbers. AVEO Pharmaceuticals had a GAAP loss of 24 cents a share in the quarter, beating the consensus by four cents a share. Revenues were up just over 230% on a year-over-year basis to $25.3 million, roughly in line with the consensus. Net FOTIVDA sales came in at $25 million, up 271% from the same period a year ago and some 24% above that of 1Q2022. Leadership reaffirmed its full year 2022 FOTIVDA U.S. net product revenue guidance of $100 million to $110 million Analyst Commentary & Balance Sheet: Since first quarter results were posted, four analyst firms including Robert W. Baird and Stifel Nicolaus have reissued Buy ratings on AVEO Pharmaceuticals. Price targets proffered range from $12 to $17 a share. Here is the note from the analyst from SVB Securities who reiterated his Buy rating and $15 price target on August 4th.
Article d’analyse • Jun 21

Rock star Growth Puts AVEO Pharmaceuticals (NASDAQ:AVEO) In A Position To Use Debt

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Seeking Alpha • May 24

AVEO Pharmaceuticals Is Primed For A Breakout

AVEO is a mostly forgotten name that is seeing very good growth in their lead product FOTIVDA. Their share price has run lower from exuberant highs reached almost 5 years ago, even as their fundamentals and future seem to be getting more solid. AVEO seems like a mostly forgotten about name that I think is poised for a big breakout higher over the next couple of years.
Article d’analyse • Mar 17

Here's What Analysts Are Forecasting For AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) After Its Annual Results

The investors in AVEO Pharmaceuticals, Inc. 's ( NASDAQ:AVEO ) will be rubbing their hands together with glee today...
Seeking Alpha • Mar 09

AVEO Pharmaceuticals: Finally Ready To Reboot

It appears as if AVEO Oncology is off to a strong start. The company is expected to report their fourth-quarter and full-year 2021 earnings on March 14th. I have stayed cautiously optimistic about AVEO’s performance in anticipation the Street will continue to be skeptical about FOTIVDA’s launch. I believe the prolonged sell-off has improved the risk-reward. My plan of remaining patient and waiting for a couple of quarters of earnings and clarity on COVID-19 appears to have saved me some pain. AVEO is now trading well below my current “buy” threshold of $4.36 per share. As a result, I am ready to reboot my AVEO position at these valuations. I will discuss how I plan to take my AVEO position out of mothball and quickly get her into the green. I am looking to buy under $3.50 per share.
Article d’analyse • Mar 03

AVEO Pharmaceuticals (NASDAQ:AVEO) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Article d’analyse • Nov 23

AVEO Pharmaceuticals (NASDAQ:AVEO) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Seeking Alpha • Oct 29

AVEO Pharmaceuticals: Sticking To The Plan

AVEO Pharmaceuticals believes that they are off to a strong start. It looks as if the first full quarter of FOTIVDA sales show there was some demand at launch. I am remaining cautiously optimistic about FOTIVDA’s launch and expect the Street to be skeptical about Aveo's commercial prospects in the coming quarters. I will discuss why I remain patient and wait for a couple more quarters of earnings and wait for the COVID headwinds to subside before getting overly bullish again. I attempt to reveal my current “buy” threshold.
Seeking Alpha • Jul 24

AVEO Pharmaceuticals: Making Its Mark In Cancer Treatment

AVEO’s lead drug candidate, Tivozanib, recently got U.S. FDA approval for treatment of Renal Cell Carcinoma. It clocked in revenue of $1.1 Million within just nine days of getting approved. Besides Tivozanib, AVEO is working on four other major drug candidates that will help in the treatment of head and neck cancer (HNSCC), cachexia, breast, pancreatic, and lung cancers. AVEO has a comprehensive portfolio of intellectual property and multiple tiers of patents that protects all of its drug candidates. The company has a strong balance sheet with adequate cash to support the research and development of its drug candidates. AVEO trades at a forward P/S ratio of 4, making it relatively undervalued when compared to the U.S. Biotechnology and Drug industry P/S ratio of ~6.5. By performing a high-level relative valuation, I arrived at an intrinsic per share value of $13.1, indicating an upside of 130% over the current share price.

Analyse de la rémunération des PDG

Comment la rémunération de Michael Bailey a-t-elle évolué par rapport aux bénéfices de AVEO Pharmaceuticals?
DateRémunération totaleSalaireBénéfices de l'entreprise
Sep 30 2022n/an/a

-US$29m

Jun 30 2022n/an/a

-US$36m

Mar 31 2022n/an/a

-US$41m

Dec 31 2021US$3mUS$590k

-US$53m

Sep 30 2021n/an/a

-US$58m

Jun 30 2021n/an/a

-US$56m

Mar 31 2021n/an/a

-US$49m

Dec 31 2020US$2mUS$565k

-US$36m

Sep 30 2020n/an/a

-US$29m

Jun 30 2020n/an/a

-US$4m

Mar 31 2020n/an/a

US$452k

Dec 31 2019US$2mUS$528k

US$9m

Sep 30 2019n/an/a

US$36m

Jun 30 2019n/an/a

-US$3m

Mar 31 2019n/an/a

US$4m

Dec 31 2018US$3mUS$528k

-US$5m

Sep 30 2018n/an/a

-US$24m

Jun 30 2018n/an/a

-US$28m

Mar 31 2018n/an/a

-US$65m

Dec 31 2017US$1mUS$480k

-US$65m

Sep 30 2017n/an/a

-US$74m

Jun 30 2017n/an/a

-US$53m

Mar 31 2017n/an/a

-US$28m

Dec 31 2016US$1mUS$444k

-US$27m

Rémunération vs marché: La rémunération totale de Michael ($USD 2.94M ) est dans la moyenne des entreprises de taille similaire sur le marché US ($USD 2.64M ).

Rémunération et revenus: La rémunération de Michael a augmenté alors que l'entreprise n'est pas rentable.

PDG

Michael Bailey (57 yo)

8yrs
Titularisation
US$2,943,905
Compensation

Mr. Michael P. Bailey serves as an Independent Chairman at IMV Inc. since May 01, 2022 and has been its Independent Director since July 20, 2020. He has been Chief Executive Officer and President of AVEO P...

Équipe de direction

NomPositionTitularisationCompensationPropriété
Michael Bailey
CEO, President & Director8yrsUS$2.94m0.98%
$ 5.1m
Erick Lucera
Chief Financial Officer3yrsUS$1.24m0%
$ 0
Michael Ferraresso
Chief Commercial Officerno dataUS$1.25m0.038%
$ 200.0k
Jeb Ledell
Chief Operating Officer1.1yrspas de données0%
$ 0
Danielle Holland
VP of Legal & Corporate Secretary2yrspas de donnéespas de données
Kevin Peacock
Senior Vice President of Marketing3.2yrspas de donnéespas de données
David Crist
Vice President of Sales2.3yrspas de donnéespas de données
Catherine DeRose
Vice President of Human Resources2.3yrspas de donnéespas de données
Lisa Bruneau
VP of Finance & Treasurer7yrspas de donnéespas de données
2.7yrs
Durée moyenne de l'emploi
54.5yo
Âge moyen

Gestion expérimentée: L'équipe de direction de AVEO est considérée comme expérimentée (ancienneté moyenne 2.7 ans).

Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
Michael Bailey
CEO, President & Director8yrsUS$2.94m0.98%
$ 5.1m
Anthony Evnin
Independent Director20.8yrsUS$127.61k0.12%
$ 627.6k
Kenneth Bate
Independent Chairman15.1yrsUS$158.73k0.0011%
$ 5.6k
Raju Kucherlapati
Member of Scientific Advisory Boardno dataUS$3.00kpas de données
Charles Sawyers
Member of Scientific Advisory Boardno datapas de donnéespas de données
H. Horvitz
Member of Scientific Advisory Boardno datapas de donnéespas de données
Tyler Jacks
Member of Scientific Advisory Boardno datapas de donnéespas de données
Lynda Chin
Member of Scientific Advisory Boardno datapas de donnéespas de données
Lewis Cantley
Member of Scientific Advisory Boardno datapas de donnéespas de données
Gregory Mayes
Independent Director3.9yrsUS$120.61k0%
$ 0
Douglas Hanahan
Member of Scientific Advisory Boardno datapas de donnéespas de données
Scarlett Spring
Independent Director3.2yrsUS$126.84k0%
$ 0
8.0yrs
Durée moyenne de l'emploi
63yo
Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de AVEO sont considérés comme expérimentés (ancienneté moyenne 8 ans).

Analyse de l'entreprise et données financières

DonnéesDernière mise à jour (heure UTC)
Analyse de l'entreprise2023/01/21 09:30
Cours de l'action en fin de journée2023/01/19 00:00
Les revenus2022/09/30
Revenus annuels2021/12/31

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

PaquetDonnéesCadre temporelExemple de source américaine *
Finances de l'entreprise10 ans
  • Compte de résultat
  • Tableau des flux de trésorerie
  • Bilan
Estimations consensuelles des analystes+3 ans
  • Prévisions financières
  • Objectifs de prix des analystes
Prix du marché30 ans
  • Cours des actions
  • Dividendes, scissions et actions
Propriété10 ans
  • Actionnaires principaux
  • Délits d'initiés
Gestion10 ans
  • L'équipe dirigeante
  • Conseil d'administration
Principaux développements10 ans
  • Annonces de l'entreprise

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.

Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

AVEO Pharmaceuticals, Inc. est couverte par 15 analystes. 1 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

AnalysteInstitution
Madhu KumarBaird
James BirchenoughBMO Capital Markets Equity Research
Madhu KumarB. Riley Securities, Inc.